STOP: Long Term PPI Monotherapy Without Microbiome Support In GERD

The Treatment Paradox

PPIs improve esophageal inflammation (IL-6 ↓38%, IL-8 ↓41%, NF-kB ↓29%) but simultaneously:

  1. Worsen gut bacterial dysbiosis — increase Enterobacteriaceae, Staphylococcaceae; deplete Bifidobacteriaceae, Ruminococcaceae, Lachnospiraceae
  2. Promote gastric Candida colonization — 96.9% detection rate; Candida significantly increases with both short and long-term PPI (shi 2023 ppi fungal dysbiosis gerd)
  3. Leave esophageal dysbiosis untreated — PPI does NOT change esophageal or oropharyngeal microbial composition despite reducing inflammatory markers (park 2020 nerd treatment esophageal microbiome)
  4. Create infection risk — increased C. difficile, Campylobacter, Shigella, Salmonella; SIBO

The Evidence for Co-Administration

In children: PPI + probiotics → 6.2% dysbiosis vs. PPI + placebo → 56.2% dysbiosis. In adults: probiotics + PPI significantly restored Bifidobacterium (6.3→9.2 lgCFU/g), reduced CRP (P=0.0486), and reduced adverse reactions from 16.6% to 6.6% (yin 2025 probiotics ppi gerd rct).

Alternative Approach

  1. Always co-administer probiotics with PPI therapy
  2. Dietary adjuncts: Mediterranean diet, low-carbohydrate diet, soluble fiber
  3. Minimize PPI duration and dose — step-down to H2RA or on-demand dosing
  4. For mild GERD: evaluate dietary-only approaches before PPI initiation

Related Articles